3 results
To determine the safety and effectiveness of the PROMUS Element* Everolimus-Eluting Coronary Stent System (Boston Scientific Corporation [BSC], Natick, MA) for the treatment of patients with up to 2 de novo atherosclerotic lesions
Objective: The response over time on daytime alertness and performance will be assessed following a single oral dose of bilastine 20 mg in healthy volunteers performing flying ability tests in a hypobaric chamber with an ambient pressure of 75.2 kPa…
The primary objective of this clinical investigation is to demonstrate that the qualification rate with anatomic lead placement is non-inferior to the qualification rate with targeted lead placement (tonic paresthesia guided) for the BurstDRTM trial…